Alimera Completes Recruitment for its Landmark NEW DAY Study
Portfolio Pulse from Benzinga Newsdesk
Alimera Sciences has completed enrollment for its NEW DAY clinical trial, a study designed to generate data for ILUVIEN, a baseline therapy for patients diagnosed with diabetic macular edema (DME).
May 24, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alimera Sciences has completed enrollment for its NEW DAY clinical trial, which aims to generate data for ILUVIEN, a therapy for diabetic macular edema.
The completion of enrollment for the NEW DAY clinical trial is a positive development for Alimera Sciences, as it moves the company closer to potentially obtaining regulatory approval for ILUVIEN. This could lead to increased revenues and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100